Bacterial Infections
Conditions
Brief summary
This is an antibiotic intervention study to determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection.
Interventions
over 50% third generation cephalosporin should be replaced by Pip/Taz
Sponsors
Wyeth is now a wholly owned subsidiary of Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients admitted or transferred to ICU/Pulmonary units * Patients of either sex, 18 years of age or older
Exclusion criteria
\- Patients who stay in units less than 48 hours will not be enrolled.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The acquisition rate of ESBL producing E. coli or K. Pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months of intervention phase) | 9 months |
Secondary
| Measure | Time frame |
|---|---|
| The infection rate due to ESBL producing E. coli or K. pnumoniae at the end of phase I (pre-intervention) and phase II (last 3 months of intervention phase) | 9 months |
Countries
China
Outcome results
None listed